Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients

International Journal of Obesity volume 28, pages 783–789 (2004)Cite this article

Abstract

OBJECTIVES: To study the effect of pioglitazone (PIO) on plasma resistin concentration, endogenous glucose production (EGP), and hepatic fat content (HFC) in patients with type II diabetes (T2DM).

SUBJECTS: A total of 13 T2DM patients (age=51±2 y, BMI=29.7±1.1 kg/m2, HbA1c=8.0±0.5%).

METHODS: HFC (magnetic resonance spectroscopy) and basal plasma resistin concentration were quantitated before and after PIO treatment (45 mg/day) for 16 weeks. Subjects received a 3 h euglycemic insulin (100 mU/m2/min) clamp with 3-[3H] glucose to determine rates of EGP and tissue glucose disappearance (Rd) before and after PIO.

RESULTS: PIO reduced fasting plasma glucose (10.3±0.7 to 7.6±0.6 mmol/l, P<0.001) and HbA1c (8.0±0.4 to 6.8±0.3%, P<0.001) despite increased body weight (83.2±3.4 to 86.3±3.4 kg, P<0.001). PIO improved Rd (4.9±0.4 to 6.6±0.5 mg/kg/min, P<0.005) and reduced EGP (0.22±0.04 to 0.06±0.02 mg/kg/min, P<0.01) during the insulin clamp. Following PIO, HFC decreased from 21.1±3.5 to 11.2±2.1% (P<0.005), and plasma resistin decreased from 5.3±0.6 to 3.5±0.3 ng/ml (P<0.01). Plasma resistin concentration correlated positively with HFC before (r=0.58, P<0.05) and after (r=0.55, P<0.05) PIO treatment. Taken collectively, plasma resistin concentration, before and after PIO treatment, correlated positively with hepatic fat content (r=0.66, P<0.001) and EGP during the insulin clamp (r=0.41, P<0.05). However, the plasma resistin concentration did not correlate with whole body glucose disposal (Rd) during the insulin clamp either before (r=−0.18, P=NS) or after (r=−0.13, P=NS) PIO treatment.

CONCLUSIONS: PIO treatment in T2DM causes a significant decrease in plasma resistin concentration. The decrease in plasma resistin is positively correlated with the decrease in hepatic fat content and improvement in hepatic insulin sensitivity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. DeFronzo RA . Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997; 5: 177–269.

    Google Scholar 

  2. Felber JP, Golay A, Jequier E, Curchod B, Temler E, DeFronzo RA, Ferrannini E . The metabolic consequences of long-term human obesity. Int J Obes Relat Metab Disord 1988; 12: 377–389.

    CAS  Google Scholar 

  3. Kahn BB, Flier JS . Obesity and insulin resistance. J Clin Invest 2000; 106: 473–481.

    Article  CAS  Google Scholar 

  4. Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, Enders GH, Silberg DG, Wen X, Wu GD, Lazar MA . A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001; 98: 502–506.

    Article  CAS  Google Scholar 

  5. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA . The hormone resistin links obesity to diabetes. Nature 2001; 409: 307–312.

    Article  CAS  Google Scholar 

  6. Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver Jr WR, Willson TM, Kliewer SA, Hotamisligil GS . Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2001; 276: 25651–25653.

    Article  CAS  Google Scholar 

  7. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S . Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50: 2199–2202.

    Article  CAS  Google Scholar 

  8. Rajala MW, Obici S, Scherer PE, Rossetti L . Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003; 111: 225–230.

    Article  CAS  Google Scholar 

  9. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA . Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300: 472–476.

    Article  CAS  Google Scholar 

  10. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S . Resistin, central obesity, and type 2 diabetes. Lancet 2002; 359: 46–47.

    Article  CAS  Google Scholar 

  11. Haugen F, Jorgensen A, Drevon CA, Trayhurn P . Inhibition by insulin of resistin gene expression in 3T3-L1 adipocytes. FEBS Lett 2001; 507: 105–108.

    Article  CAS  Google Scholar 

  12. McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL, Clark PM, Smith SA, Barnett AH, Kumar S . Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003; 88: 6098–6106.

    Article  CAS  Google Scholar 

  13. Smith SR, Bai F, Charbonneau C, Janderova L, Argyropoulos G . A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes 2003; 52: 1611–1618.

    Article  CAS  Google Scholar 

  14. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA . Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003; 52: 1364–1370.

    Article  CAS  Google Scholar 

  15. Goto T, Onuma T, Takebe K, Kral JG . The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. Int J Obes Relat Metab Disord 1995; 19: 841–845.

    CAS  Google Scholar 

  16. Ryysy L, Hakkinen A, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Jarvinen H . Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorbtion are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000; 49: 749–758.

    Article  CAS  Google Scholar 

  17. Banerji MA, Buckley MC, Chaiken RL, Gordon D, Lebovitz HE, Kral JG . Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord 1995; 19: 846–850.

    CAS  PubMed  Google Scholar 

  18. Kawasaki T, Hashimoto N, Kikuchi T, Takahashi H, Uchiyama M . The relationship between fatty liver and hyperinsulinemia in obese Japanese children. J Pediatr Gastroenterol Nutr 1997; 24: 317–321.

    Article  CAS  Google Scholar 

  19. Silverman JF, Pories WJ, Caro JF . Liver pathology in diabetes mellitus and morbid obesity: clinical, pathological, and biochemical considerations. Pathol Annu 1989; 24: 275–302.

    PubMed  Google Scholar 

  20. Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC . Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003; 285: E906–E916.

    Article  CAS  Google Scholar 

  21. DeFronzo R, Tobin J, Andres R . Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214–E223.

    CAS  Google Scholar 

  22. DeFronzo RA . Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281–303.

    Article  CAS  Google Scholar 

  23. Bottomley PA . Spatial localization in NMR spectroscopy in vivo. Ann NY Acad Sci 1987; 508: 333–348.

    Article  CAS  Google Scholar 

  24. Groop LC, Bonadonna RC, Del Prato S, Ratheiser K, Zyck K, DeFronzo RA . Glucose and free fatty acid metabolism in non-insulin-dependant diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 1989; 84: 205–213.

    Article  CAS  Google Scholar 

  25. Steele R . Influence of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 1959; 82: 420–430.

    Article  CAS  Google Scholar 

  26. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA . An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953–12956.

    Article  CAS  Google Scholar 

  27. Hallakou S, Doare F, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF, Dugail I, Morin J, Auwerx J, Ferre P . Pioglitazone induces in vivo adipocyte differentiation in obese Zucker fa/fa rat. Diabetes 1997; 46: 1393–1399.

    Article  CAS  Google Scholar 

  28. Lambe KG, Tugwood JD . A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biochem 1996; 239: 1–7.

    Article  CAS  Google Scholar 

  29. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA . Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784–2791.

    Article  CAS  Google Scholar 

  30. Miyazaki Y, Hardies LJ, Wajcberg E, Glass L, Triplett C, Bajaj M, Cersosimo E, Mandarino LJ, DeFronzo RA . Effect of pioglitazone on liver fat content, abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus. Diabetes 2002; 51 (Suppl 2): 69A.

    Google Scholar 

  31. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF . The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797–802.

    Article  CAS  Google Scholar 

  32. Shojima N, Sakoda H, Ogihara T, Fujishiro M, Katagiri H, Anai M, Onishi Y, Ono H, Inukai K, Abe M, Fukushima Y, Kikuchi M, Oka Y, Asano T . Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 2002; 51: 1737–1744.

    Article  CAS  Google Scholar 

  33. Moore GB, Chapman H, Holder JC, Lister CA, Piercy V, Smith SA, Clapham JC . Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice. Biochem Biophys Res Commun 2001; 286: 735–741.

    Article  CAS  Google Scholar 

  34. Yang RZ, Huang Q, Xu A, McLenithan JC, Eison JA, Shuldiner AR, Alkan S, Gong DW . Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun 2003; 310: 927–935.

    Article  CAS  Google Scholar 

  35. Kim KH, Lee K, Moon YS, Sul HS . A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001; 276: 11252–11256.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the nurses on the GCRC for their diligent care of our patients and especially Patrcia Wolff RN, Norma Diaz BSN, James King RN and John Kincade RN for carrying out the insulin clamp studies. We gratefully acknowledge the technical assistance of Richard Castillo, Kathy Camp, Cindy Munoz, and Sheila Taylor. Ms Lorrie Albarado and Ms Elva Chapa provided skilled secretarial support in the preparation of the manuscript. This work was supported in part by grants from Takeda America, NIH Grant DK-24092, a VA Merit Award, and GCRC Grant MO1-RR01346.

Author information

Authors and Affiliations

  1. Diabetes Division, Department of Medicine, University of Texas Health Science Center at San Antonio, Texas

    M Bajaj, S Suraamornkul, L J Hardies, T Pratipanawatr & R A DeFronzo

Authors
  1. M Bajaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Suraamornkul
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L J Hardies
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Pratipanawatr
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R A DeFronzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Bajaj.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bajaj, M., Suraamornkul, S., Hardies, L. et al. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes 28, 783–789 (2004). https://doi.org/10.1038/sj.ijo.0802625

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0802625

Keywords

This article is cited by

Search

Advanced search

Quick links